5 Stocks Pushing The Health Care Sector Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 48 points (0.3%) at 16,465 as of Friday, Jan. 17, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,451 issues advancing vs. 1,447 declining with 177 unchanged.

The Health Care sector currently sits up 0.5% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the sector include Edwards Life ( EW), down 4.6%, Herbalife ( HLF), down 4.2%, Grifols ( GRFS), down 1.6%, St Jude Medical ( STJ), down 1.0% and Pfizer ( PFE), down 0.6%. Top gainers within the sector include Intercept Pharmaceuticals ( ICPT), up 10.8%, Align Technology ( ALGN), up 3.6%, Intuitive Surgical ( ISRG), up 2.9%, Jazz Pharmaceuticals ( JAZZ), up 2.5% and Shire ( SHPG), up 1.6%.

TheStreet would like to highlight 5 stocks pushing the sector lower today:

5. Mindray Medical International Limited ADR r ( MR) is one of the companies pushing the Health Care sector lower today. As of noon trading, Mindray Medical International Limited ADR r is down $1.99 (-5.0%) to $38.21 on heavy volume. Thus far, 971,125 shares of Mindray Medical International Limited ADR r exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $37.50-$40.00 after having opened the day at $38.95 as compared to the previous trading day's close of $40.20.

Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray, develops, manufactures, and markets medical devices worldwide. It operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. Mindray Medical International Limited ADR r has a market cap of $4.7 billion and is part of the health services industry. The company has a P/E ratio of 21.6, above the S&P 500 P/E ratio of 17.7. Shares are up 10.4% year-to-date as of the close of trading on Thursday. Currently there are 5 analysts that rate Mindray Medical International Limited ADR r a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Mindray Medical International Limited ADR r as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Mindray Medical International Limited ADR r Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Catamaran ( CTRX) is down $0.69 (-1.4%) to $49.55 on light volume. Thus far, 582,543 shares of Catamaran exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $49.14-$50.08 after having opened the day at $50.08 as compared to the previous trading day's close of $50.24.

Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments: PBM and HCIT. Catamaran has a market cap of $10.2 billion and is part of the health services industry. The company has a P/E ratio of 44.0, above the S&P 500 P/E ratio of 17.7. Shares are up 5.8% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts that rate Catamaran a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Catamaran as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, impressive record of earnings per share growth and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Catamaran Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Novartis ( NVS) is down $0.46 (-0.6%) to $81.32 on light volume. Thus far, 398,158 shares of Novartis exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $81.31-$81.64 after having opened the day at $81.58 as compared to the previous trading day's close of $81.78.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $196.8 billion and is part of the drugs industry. The company has a P/E ratio of 20.8, above the S&P 500 P/E ratio of 17.7. Shares are up 1.7% year-to-date as of the close of trading on Thursday. Currently there are 3 analysts that rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Novartis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Covidien ( COV) is down $1.04 (-1.5%) to $68.64 on average volume. Thus far, 1.1 million shares of Covidien exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $68.62-$69.64 after having opened the day at $69.44 as compared to the previous trading day's close of $69.68.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $31.7 billion and is part of the health services industry. The company has a P/E ratio of 20.6, above the S&P 500 P/E ratio of 17.7. Shares are up 2.3% year-to-date as of the close of trading on Thursday. Currently there are 14 analysts that rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Baxter International ( BAX) is down $0.40 (-0.6%) to $69.66 on light volume. Thus far, 998,922 shares of Baxter International exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $69.52-$70.12 after having opened the day at $70.02 as compared to the previous trading day's close of $70.06.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $37.9 billion and is part of the health services industry. The company has a P/E ratio of 17.7, equal to the S&P 500 P/E ratio of 17.7. Shares are up 0.7% year-to-date as of the close of trading on Thursday. Currently there are 5 analysts that rate Baxter International a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Baxter International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices